Global Cancer Supportive Care Drugs Market, By Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Melanoma, Others), Therapeutic Class (Bisphosphonates, Opioids, Anti-emetics, Nonsteroidal anti-inflammatory drug (NSAIDs), Erythropoiesis Stimulating Agents (ESAs), Granulocyte-Colony Stimulating Factors (G-CSFs), Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights : Global Cancer Supportive Care Drugs Market
Cancer supportive care drugs market is expected to gain market growth in the forecast period of 2021-2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 1.85% in the above mentioned forecast period.
Supportive treatment which is employed in the mitigation of several types of cancer, improves survival and quality of life. Cancer supportive care aims to relieve patients of the negative consequences of cancer therapy and treatments. Cancer related side-effects and their accompanying side effects can be prevented and treated with the help of supportive cancer care medications. Anaemia, nausea, vomiting and poor appetite are all side effects of cancer treatment. Some of the drugs utilized in supportive care are Rasburicase, mesna, folinic acid, dexrazoxane allopurinol, and amifostine. The Multinational Association for Cancer Supportive Care has developed a scoring criterion to identify individuals with low-risk febrile neutropenia.
The rise in the prevalence of cancer and the rise in the number of people suffering from the side effects of anti-cancer therapies are the major factors driving the market growth. Furthermore, growing consumption of biosimilar drugs, development in the healthcare infrastructure and rising initiatives by government and private organisations for spreading and formulating awareness program are the factors that will expand the cancer supportive care drugs market.
Rise in the research and development activities and emerging markets will provide beneficial opportunities for the cancer supportive care drugs market in the forecast period of 2021-2028.
However, high cost of medication and side effects associated with cancer supportive care drugs are the factors that will hinder the market growth and strict rules and regulations will challenge the cancer supportive care drugs market in the forecast period mentioned above.
This cancer supportive care drugs market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cancer supportive care drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Cancer Supportive Care Drugs Market Scope and Market Size
The cancer supportive care drugs market is segmented on the basis of cancer type, therapeutic class, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of cancer type, the cancer supportive care drugs market is segmented into lung cancer, prostate cancer, breast cancer, melanoma and others.
- On the basis of therapeutic class, the cancer supportive care drugs market is segmented into bisphosphonates, opioids, anti-emetics, nonsteroidal anti-inflammatory drug (NSAIDs), erythropoiesis stimulating agents (ESAs), granulocyte-colony stimulating factors (G-CSFs) and others. Others have been further sub-segmented into antineoplastic antibiotics and neutropenia.
- On the basis of end-users, the cancer supportive care drugs market is segmented into clinic, hospital and others.
- The cancer supportive care drugs market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Cancer Supportive Care Drugs Market Country Level Analysis
The cancer supportive care drugs market is segmented on the basis of cancer type, therapeutic class, end-users and distribution channel.
The countries covered in the cancer supportive care drugs market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the cancer supportive care drugs market due to the presence of major key players, growing prevalence of cancer, high disposable income, high healthcare expenditure and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, rising investment in the healthcare sector, emergence of small players and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Cancer supportive care drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Cancer Supportive Care Drugs Market Share Analysis
Cancer supportive care drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global cancer supportive care drugs market research.
The major players covered in the cancer supportive care drugs market report are Amgen Inc., Novartis AG, Merck Sharp & Dohme Corp., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd, Helsinn Healthcare SA, Heron Therapeutics, Inc., GlaxoSmithKline plc, Purdue Pharma L.P., Baxter, Fagron, Teva Pharmaceuticals Industries Ltd., APR, Kyowa Kirin Co., Ltd. and Acacia Pharma Group Plc., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-